Overview
Clover's TNF Receptor Detection Methodology Published in Scientific Reports
2017-07-31
CHENGDU, CHINA – 31 July 2017 – Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies for oncology and autoimmune diseases, today announced the publication of its new method, that was developed in-house, to functionally detect TNF receptor family members by affinity-labeled ligands in Scientific Reports.  
 
Publication details are as follows:
Title: “Functional Detection of TNF Receptor Family Members by Affinity-Labeled Ligands”
Authors: Yang Xu, Lingmo Chang, Anliang Huang, Xioajun Liu, Xinyu Liu, Hong Zhou, Joshua G. Liang, Peng Liang
Publication: Scientific Reports 7 (1):6944. DOI: 10.1038/s41598-017-06343-4
Available Online: www.nature.com/articles/s41598-017-06343-4
 
“We are delighted to have our research peer-reviewed and published in Scientific Reports,” said Dr. Peng Liang, co-founder, Chairman and President. “Given that the TNF superfamily of receptors and ligands play critical roles in many oncology and autoimmune diseases, our new methodology may be an important tool for biomarker detection in clinical trials and in real-world practice.”
 
 
About Clover Biopharmaceuticals
Clover Biopharmaceuticals is a global, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house biomanufacturing capabilities to develop select biosimilars. For more information, please visit our website: www.cloverbiopharma.com.





上一篇:Clover Held its 2016 Board Meeting in Chengdu
下一篇:SCB-313 Preclinical Data Published in Scientific Reports